Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report

被引：1
作者：
Cabral, Sara Cerqueira [1 ]
Gouveia, Emanuel [1 ]
Nunes, Hugo [1 ]
Pereira, Patricia M. [1 ]
机构：
[1] Inst Portugues Oncol Lisboa Francisco Gentil EPE, Med Oncol Dept, Lisbon, Portugal
来源：
CASE REPORTS IN ONCOLOGY | 2024年 / 17卷 / 01期
关键词：
Cutaneous squamous cell carcinoma; Preoperative therapy; Cemiplimab; Case report; CEMIPLIMAB; CSCC;
D O I：
10.1159/000540842
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting. Case Presentation: Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection. Conclusion: This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.
引用
收藏
页码：1109 / 1114
页数：6
相关论文
共 14 条
  • [1] Migden M.R., Rischin D., Schmults C.D., Guminski A., Hauschild A., Lewis K.D., Et al., PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma, N Engl J Med., 379, 4, pp. 341-351, (2018)
  • [2] Stratigos A.J., Garbe C., Dessinioti C., Lebbe C., Van Akkooi A., Bataille V., Et al., European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma.Part 1: diagnostics and preventionupdate 2023, Eur J Cancer., 193, (2023)
  • [3] Migden M., Lewis K., Schmults C., Khushanlani N., Guminski A., Chang A., Et al., 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3, Ann Oncol., 33, pp. S918-S919, (2022)
  • [4] Gross N.D., Miller D.M., Khushalani N.I., Divi V., Ruiz E.S., Lipson E.J., Et al., Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma, N Engl J Med., 387, 17, pp. 1557-1568, (2022)
  • [5] Zuur C.L., Breukers S., MacHuca-Ostos M., Boere T., Smit L., De Boer J., Et al., Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: an investigator-initiated randomized phase II trial-the MATISSE trial, J Clin Oncol., 41, 16, (2023)
  • [6] Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma, J Clin Oncol., 41, 16, (2023)
  • [7] Amatore F., Sridharan S., Karunamurthy A., Wang H., Patel R., Pugliano-Mauro M., Et al., Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC), J Clin Oncol., 42, 16, (2024)
  • [8] Guven D.C., Sahin T.K., Rizzo A., Ricci A.D., Aksoy S., Erul E., Et al., The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis, Front Mol Biosci., 9, (2022)
  • [9] Zhang Y., Chen S., Chen H., Li W., A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer, Cancer Med., 12, 1, pp. 38-48, (2023)
  • [10] Baggi A., Quaglino P., Rubatto M., Depenni R., Guida M., Ascierto P.A., Et al., Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma, Eur J Cancer., 157, pp. 250-258, (2021)
12